Drug General Information (ID: DDIN4OXFHT)
  Drug Name Diclofenamide Drug Info Milnacipran Drug Info
  Drug Type Small molecule Small molecule
  Therapeutic Class Ophthalmic Glaucoma Agents Antidepressants
  Structure

 Mechanism of Diclofenamide-Milnacipran Interaction (Severity Level: Moderate)
     Increased risk of hyponatremia Click to Show/Hide Mechanism Graph
Could Not Find 2D Structure
      Drug Name Diclofenamide Milnacipran
      Mechanism Hyponatremia Hyponatremia
      Key Mechanism Factor 1
Factor Name Hyponatremia
Factor Description Hyponatremia is a condition in which the amount of sodium in the blood is lower than normal. Symptoms of hyponatremia may include: nausea and vomiting, fatigue, headache or confusion, muscle cramps, weakness, irritability and restlessness.
      Mechanism Description
  • Increased risk of hyponatremia by the combination of Diclofenamide and Milnacipran 

Recommended Action
      Management Caution is recommended if SSRIs or SNRIs are prescribed in combination with diuretics, particularly in the elderly. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hyponatremia such as nausea, vomiting, headache, malaise, lethargy, irritability, difficulty concentrating, memory impairment, confusion, weakness, muscle spasm, and unsteadiness (which may lead to falls). More severe and/or acute cases may include hallucination, syncope, seizure, coma, respiratory arrest, and death. Discontinuation of SSRI/SNRI therapy should be considered in patients who develop symptomatic hyponatremia, and appropriate medical intervention instituted as necessary. Patients should also have their blood pressure and pulse monitored before and during SSRI/SNRI therapy, especially during the first few weeks and following a dosage increase. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.

References
1 Product Information. Savella (milnacipran). Forest Pharmaceuticals, St. Louis, MO.
2 Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996): 885. [PMID: 8826582]
3 Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995): 809-10. [PMID: 7726326]